LGALS9 and B-cell chronic lymphocytic leukemia: Also, the median TTFT for CLL patients with high galectin-9 levels was 4 months (95% CI, 0–27 months, n = 47), which is significantly shorter than in patients with low serum galectin-9 levels (23 months, 95% CI, 0.5–43 months, n = 44, p < 0.0001).